Literature DB >> 2779175

The determination of the anticoagulant rodenticide brodifacoum in blood serum by liquid chromatography with fluorescence detection.

L J Felice1, M J Murphy.   

Abstract

A sensitive method utilizing reversed-phase liquid chromatography with fluorescence detection has been developed for the analysis of the anticoagulant rodenticide brodifacoum in blood serum. The serum proteins are precipitated with acetonitrile and the supernatant mixed with ethyl ether. The organic phase is separated, evaporated to dryness, and the residue subjected to chromatographic analysis. Extraction efficiencies of brodifacoum at concentrations of 20, 60, and 300 ng/mL were 82.9, 93.4, and 93.8%, respectively, with coefficients of variation (CVs) of 3.52, 4.07, and 3.68%, respectively. The intrarun precision (CV) without an internal standard at concentrations of 20, 60, and 300 ng/mL were 1.93, 4.89, and 1.51%, respectively, and 3.56, 5.94, and 3.66% with an internal standard. The interrun precision over the concentration range of 20-1000 ng/mL ranged from 1.88-6.22% without an internal standard and from 2.07-12.6% with an internal standard. Brodifacoum was measurable to at least the 1-ng/mL level.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2779175     DOI: 10.1093/jat/13.4.229

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  3 in total

1.  Superwarfarin ingestion.

Authors:  D V Exner; W F Brien; M J Murphy
Journal:  CMAJ       Date:  1992-01-01       Impact factor: 8.262

2.  Clinical signs, laboratory changes and toxicokinetics of brodifacoum in the horse.

Authors:  H J Boermans; I Johnstone; W D Black; M Murphy
Journal:  Can J Vet Res       Date:  1991-01       Impact factor: 1.310

3.  Separation and Quantification of Superwarfarin Rodenticide Diastereomers-Bromadiolone, Difenacoum, Flocoumafen, Brodifacoum, and Difethialone-in Human Plasma.

Authors:  Daniel G Nosal; Douglas L Feinstein; Luying Chen; Richard B van Breemen
Journal:  J AOAC Int       Date:  2020-06-01       Impact factor: 2.028

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.